Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This Phase II study will assess the efficacy, safety, and pharmacodynamics and pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with relapsed adenocarcinoma of the esophagus, including tumors of the GE junction and gastric cardia.
Epistemonikos ID: 0ad480dcc80256d750c262a610f75b679349fe18
First added on: May 04, 2024